23 Aug, 2016 J&J Won’t Give Up On Remicade Patent By Andrew Steinberg | Drug & Device Manufacturers | 0 Comments Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade will now be competing with a cheaper biosimilar. Just last week, a judge ruled the patent protecting the medication was invalid,... Read More
